Effect of biological disease-modifying antirheumatic drugs on body composition in patients with rheumatoid arthritis: a systematic review and meta-analysis

• Published in: Advances in rheumatology (London, England) Vol. 62; no. 1; p. 16
• Main Authors: de Souza, Mariana Peixoto Guimarães Ubirajara E Silva, Guimarães, Nathalia Sernizon, de Resende Guimarães, Maria Fernanda Brandão, de Souza, Viviane Angelina, Kakehasi, Adriana Maria
• Format: Journal Article
• Language: English
• Published: England Sociedade Brasileira de Reumatologia 23-05-2022; BMC
• Subjects: Body composition; Disease-modifying antirheumatic drugs; Fat free mass; Rheumatoid arthritis; Rheumatoid cachexia; RHEUMATOLOGY; Fat free mass; Rheumatoid cachexia; Disease-modifying antirheumatic drugs; Rheumatoid arthritis; Body composition
• ISSN: 2523-3106; 2523-3106
• DOI: 10.1186/s42358-022-00249-0

Rheumatoid arthritis (RA) generates an inflammatory profile that predisposes to total and visceral fatty accumulation and reduced fat free mass (FFM). This metabolic disorder contributes to poor functionality, increased cardiovascular risk and higher mortality. This study aimed to address a systematic review with meta-analysis to determine the effect of biological and targeted synthetic disease-modifying antirheumatic drugs (bDMARDs and tsDMARDs) on body composition (BC) of patients with RA.
The search was conducted at the electronic databases PubMed, Cochrane Library, Embase, Lilacs and grey literature. This investigation was carried until July 2021. Outcomes of interest were total weight, body mass index (BMI), fat mass (FM) and FFM. A meta-analysis comparing these outcomes in RA patients under bDMARD treatment versus controls was performed.
Out of 137 studies reviewed, 18 were selected: fifteen prospective cohorts, two retrospective cohorts, and one cross-sectional study. The studies comprised 1221 patients, 778 on bDMARD treatment and 443 controls, which included RA patients under conventional synthetic DMARD (csDMARD). No study addressing BC analysis in patients using tsDMARD was found. The mean age and duration of the disease was 56.7 years and 6.77 years, respectively. Ten studies demonstrated a significant increase of total weight in 88.2% of patients and 42.3% for BMI. In studies that analyzed BC by double X-ray absorptiometry (DXA), the increase in total weight and BMI correlated positively to the increase in FFM. The meta-analysis carried out in five studies showed no significant difference of the mean difference for total weight 0.12 kg (95% CI - 5.58, 5.82), BMI 0.08 kg/m
(95% CI - 1.76, 1.92), FM - 0.08 kg (95% IC - 5.31, 5.14), and FFM - 2.08 kg (95% CI - 7.37, 3.21).
This systematic review suggests a possible impact of bDMARDs on BC of RA patients, even though, the meta-analysis carried out in a small part of these studies was not able to confirm significant variation in BC components.
PROSPERO code: CRD42020206949.